Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) (NCT05549297)
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (82 Sites)
Showing the first 25 of 82 sites.
- Mayo Clinic Arizona — Phoenix, Arizona
- Mayo Clinic Florida — Jacksonville, Florida
- Orlando Health Cancer Institute — Orlando, Florida
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- University of Kansas Cancer Center - Westwood — Westwood, Kansas
- St Elizabeth Healthcare (St Elizabeth Medical Center) — Edgewood, Kentucky
- St Elizabeth Healthcare (St Elizabeth Medical — Edgewood, Kentucky
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Minnesota Medical Center — Minneapolis, Minnesota
- Mayo Clinic Minnesota — Rochester, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Northwell Health Cancer Institute - Zuckerberg Cancer Center — Lake Success, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
- Thomas Jefferson University Medical Oncology Clinic — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- Gibbs Cancer Center and Research Institute — Spartanburg, South Carolina
- University of Tennessee Medical Center — Knoxville, Tennessee
- Houston Methodist Hospital/Houston Methodist Cancer Center — Houston, Texas
- University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (844) 466-8661
Email: medical.information@immunocore.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Melanoma
- Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — Fairhope, Alabama
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — Birmingham, Alabama
- Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — Mobile, Alabama
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — Scottsdale, Arizona
- A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma — Pittsburgh, Pennsylvania
- Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors — St Louis, Missouri
Explore by condition: All Advanced Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.